A multi-kinase inhibitor; inhibits FLT3, CSF1R, c-Kit, FGFR1, FGFR3, VEGFR1, -2, and -3, PDFGRα, and PDGFRβ (IC50s = 1, 36, 2, 8, 9, 10, 13, 8, 27, and 210 nM, respectively); inhibits the proliferation of human multiple myeloma cell lines expressing mutant, but not wild-type, FGFR3 (IC50s = 90-550 and >2,500 nM, respectively); decreases FGF-induced ERK1/2 phosphorylation and induces apoptosis in patient-derived multiple myeloma cells at 500 nM; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice at 3-300 mg/kg for 8 days; reduces tumor growth in KM12L4A, DU145, and MV4-11 mouse xenograft models (ED50s = 17, 23, and 3 mg/kg per day, respectively)